DXCMDexcom

Health care · Medical Instruments · Nasdaq

We are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians around the world. 10-K, Item 1

Employees: 11,100
Headquarters: San Diego, CA
CEO: Jacob Steven Leach
Next results: around Jan 11, 2027

Compare with peers → Embed

The numbers DXCM said it expected, in its earnings releases of the last 3 years, next to what it then reported for the same period. Each target links to the sentence in the release; each result to the 10-Q or 10-K it was first reported in.

Of 2 range targets with a reported result: 0 came in above the last range given, 1 within it, 1 below it.

Target	What the company said	Reported	Result
Revenue Fiscal 2026	Given $5.16B to $5.25B release 2026-01-12	–	Not reported yet
The company's words For 2026, Dexcom currently anticipates total revenue of $5.16 - $5.25 billion, representing expected growth of approximately 11-13% over 2025. release 2026-01-12
Revenue (company-defined) Fiscal 2026	Given $5.16B to $5.25B release 2026-02-12 Kept $5.16B to $5.25B release 2026-04-30 Raised $5.18B to $5.25B release 2026-07-30 Raised $5.20B to $5.25B release 2026-10-29	–	No standard number
The company's words Dexcom is reiterating fiscal year 2026 guidance for Revenue, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and establishing Adjusted EBITDA Margin guidance at the following levels: … Revenue of $5.16 - $5.25 billion (approximately 11-13% growth) release 2026-02-12 Dexcom is raising fiscal year 2026 guidance for Non-GAAP Operating Margin and Adjusted EBITDA Margin, and reiterating guidance for Revenue and Non-GAAP Gross Profit Margin at the following levels: … Revenue of $5.16 - $5.25 billion (approximately 11-13% growth) release 2026-04-30 Dexcom is raising the midpoint of fiscal year 2026 Revenue guidance and increasing fiscal year 2026 guidance for Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin to the following levels: … Revenue of $5.18 - $5.25 billion (approximately 11-13% growth) release 2026-07-30 Dexcom is raising the midpoint of fiscal year 2026 Revenue guidance, reiterating fiscal year 2026 Non-GAAP Gross Profit Margin guidance, and increasing fiscal year 2026 guidance for Non-GAAP Operating Margin and Adjusted EBITDA Margin to the following levels: … Revenue of $5.20 - $5.25 billion (approximately 12-13% growth) release 2026-10-29
Revenue (company-defined) Fiscal 2025 (ended 2025-12-31)	Given $4.60B to $4.62B release 2025-07-30 Raised $4.63B to $4.65B release 2025-10-30	–	No standard number
The company's words Dexcom is raising fiscal year 2025 guidance for Revenue, and reiterating guidance for Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin at the following levels: … Revenue of $4.600 - $4.625 billion (14-15% growth) release 2025-07-30 Dexcom is raising fiscal year 2025 guidance for Revenue, and updating guidance for Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin at the following levels: … Revenue of $4.630 - $4.650 billion (approximately 15% growth) release 2025-10-30
Revenue Fiscal 2024 (ended 2024-12-31)	Given $4.15B to $4.35B release 2024-01-08	$4.03B 10-K filed 2025-02-18	Below the range
The company's words For 2024, Dexcom currently anticipates total revenue of approximately $4.15 billion to $4.35 billion, representing expected organic growth 1 of approximately 16% to 21% over 2023. release 2024-01-08
Revenue (company-defined) Fiscal 2024 (ended 2024-12-31)	Given $4.15B to $4.35B release 2024-02-08 Raised $4.20B to $4.35B release 2024-04-25 Lowered $4.00B to $4.05B release 2024-07-25 Kept $4.00B to $4.05B release 2024-10-24	–	No standard number
The company's words The company is reiterating fiscal year 2024 guidance for Revenue, Non-GAAP Gross Profit Margin and Non-GAAP Operating Margin, and establishing Adjusted EBITDA Margin guidance at the following levels: … Revenue of approximately $4.15 - 4.35 billion (16 - 21% organic growth 3 ) release 2024-02-08 Dexcom is updating fiscal year 2024 guidance for Revenue, and reiterating guidance for Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin at the following levels: … Revenue of approximately $4.20 - 4.35 billion (17 - 21% organic growth 2 ) release 2024-04-25 Dexcom is updating fiscal year 2024 guidance for Revenue and Non-GAAP Gross Profit Margin, and reiterating guidance for Non-GAAP Operating Margin and Adjusted EBITDA Margin at the following levels: … Revenue of approximately $4.00 - 4.05 billion (11 - 13% organic growth 2 ) release 2024-07-25 Dexcom is reiterating fiscal year 2024 guidance for Revenue, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin at the following levels: … Revenue of approximately $4.00 - 4.05 billion (11 - 13% organic growth 2 ) release 2024-10-24
Revenue Q3 of fiscal 2024	Given $975.00M to $1.00B release 2024-07-25	$994.20M 10-Q filed 2024-10-24	Within the range
The company's words In addition, to account for certain unique items impacting 2024 seasonality, the company is establishing guidance for third quarter 2024 Revenue of approximately $975 million to $1.00 billion (1 - 3% organic growth). release 2024-07-25

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (15 releases since 2024-01-08), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Work on DXCM in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/DXCM/export.csv") into a cell.